Chin. J. Org. Chem. ›› 2016, Vol. 36 ›› Issue (6): 1419-1425.DOI: 10.6023/cjoc201512034 Previous Articles     Next Articles

Notes

苯并[f][1,4]氧氮杂?酮衍生物的合成及抗肿瘤活性研究

李凤琼a, 穆敏婕a, 杨娜b, 钟凌b, 胡荣a, 李晋奇白兰b,, 师健友b, 张梅b   

  1. a 成都中医药大学药学院 中药材标准化教育部重点实验室 中药资源系统研究与开发利用省部共建国家重点实验室培育基地 成都 611137;
    b 四川省医学科学院·四川省人民医院 电子科技大学附属医院 个体化药物治疗四川省重点实验室 成都 610072
  • 收稿日期:2015-12-23 修回日期:2016-01-22 发布日期:2016-02-18
  • 通讯作者: 师健友, 张梅 E-mail:shijianyoude@126.com;zhangmei63@126.com
  • 基金资助:

    国家自然科学基金(No.81302643)、中国博士后科学基金面上(No.2014M552374)资助项目.

Synthesis and Anticancer Activity Evaluation of Benzo[f][1,4]oxazepinone Derivatives

Li Fengqionga, Mu Minjiea, Yang Nab, Zhong Lingb, Hu Ronga, Li Jinqib,, Bai Lanb, Shi Jianyoub, Zhang Meia   

  1. aKey Laboratory of Standardization of Chinese Herbal Medicines of Ministry of Education, State Key Laboratory Breeding Base of Systematic Research, Development and Utilization of Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine (TCM), Chengdu 611137;
    b Sichuan Provincial Key Laboratory of Individualized Drug Therapy, Sichuan Academy of Medical Science & SichuanProvincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China (UESTC), Chengdu 610072
  • Received:2015-12-23 Revised:2016-01-22 Published:2016-02-18
  • Supported by:

    Project supported by the National Natural Science Foundation of China (No. 81302643), and the China Postdoctoral Science Foundation (No. 2014M552374).

The telomere-associated protein tankyrase is a poly(adenosine diphosphate-ribose) polymerase and is considered to be a promising target for cancer therapy, especially selective lethality on breast cancer associated (BRCA) cell lines, including breast cancer as well as malignancies of the ovaries, pancreas, and prostate gland. A variety of drug candidates have been developed and investigated, such as XAV-939, which was identified as a tankyrase inhibitor during screening for a small-mole- cule inhibitor of the Wnt/β-catenin pathway, and it exhibits nanomolar activity in the tankyrase-2 biochemical assay. Coincidentally, almost all compounds which exhibit excellent activity in the tankyrase-2 biochemical assay showed the common structure: lactam ring or amide structure. According to the reported co-crystal structure of inhibitors with tankyrase-2 analysis, it was found that the lactam ring or amide of the compounds forms three conserved hydrogen bonds to Gly1032 and Ser1068 and a π-stacking interaction with Tyr1071. Thus the lactam ring or amide was identified to be a key structure of tankyrase inhibitors. So a new class of structure based on benzo[f][1,4]oxazepinone scaffold was designed through computer-aided virtual drug screening, and 12 new compounds were synthesized via Mannich reactions of aromatic aldehydes with aromatic amines and aromatic ketones, ring expansion, reduction and condensation. The target compound was confirmed by 1H NMR, 13C NMR, HRMS. Followed by the methyl thiazolyl tetrazolium (MTT) assay [A1] to test in vitro anti-tumor activity, part compounds showed potent inhibitory effect on tumor cells. This study culminates in compound 3h, an inhibitor with potent activity against Hep-3B (IC50=3.5 μmol/L). Here, the synthesis and structure-activity relationship (SAR) of this novel series were described. To explore the anti-tumor mechanism of benzo[f][1,4]oxazepinone compounds, we explored the interaction of the compound 3h complex with the Gly1032, Ser1068 and Tyr1071 binding site of tankyrase-2, which confirms the three conserved hydrogen and π-stacking binding mode, as supporting information for the in vitro anti-tumor activity.

Key words: benzo[f][1,4]oxazepin-one, derivatives, tankyrase, anticancer, structure-activity relationship